Target Name: TECR
NCBI ID: G9524
Review Report on TECR Target / Biomarker Content of Review Report on TECR Target / Biomarker
TECR
Other Name(s): synaptic glycoprotein SC2 | trans-2,3-enoyl-CoA reductase | SC2 | Very-long-chain enoyl-CoA reductase (isoform 1) | TECR_HUMAN | TECR variant 1 | Trans-2,3-enoyl-CoA reductase, transcript variant 1 | TER | glycoprotein, synaptic 2 | Glycoprotein, synaptic 2 | Synaptic glycoprotein SC2 | epididymis secretory sperm binding protein | GPSN2 | MRT14 | Very-long-chain enoyl-CoA reductase | Trans-2,3-enoyl-CoA reductase

TECR: A Promising Drug Target and Biomarker for Synaptic Glycoprotein SC2

Introduction

Synaptic glycoprotein SC2 is a protein that plays a crucial role in the structure and function of the synapses, which are the structural elements that connect nerve cells to transmit signals. Mutations in SC2 have been linked to various neurological disorders, including epilepsy, bipolar disorder, and schizophrenia. Therefore, identifying potential drug targets and biomarkers for SC2 has become an important research focus. In this article, we will explore TECR, a drug target and biomarker for SC2.

TECR: A Potential Drug Target

TECR (Tectin-like Early-Response protein) is a type-I transmembrane protein that is expressed in various tissues, including brain, heart, and muscle. It is characterized by a unique N-terminal domain that consists of a long coiled-coil region and a catalytic alpha-helicase domain. The alpha-helicase domain is responsible for the protein's unique 灏?-sheet-灏?-sheet structure, which is unique among SC2 proteins. TECR has been shown to play a role in various physiological processes, including cell signaling, cytoskeletal organization, and neurotransmission.

Several studies have suggested that TECR may be a potential drug target for SC2-related disorders. For instance, overexpression of TECR has been shown to increase the levels of SC2 in brain tissue, which could potentially contribute to the neurotoxicity associated with SC2-related disorders (3 ). Additionally, TECR has been shown to interact with various signaling pathways, including the TGF-灏? pathway. This suggests that TECR may be involved in the regulation of cellular processes that are critical for neuronal function and development, including synaptic development and plasticity.

TECR as a Biomarker

In addition to its potential as a drug target, TECR has also been suggested as a potential biomarker forSC2-related disorders. Several studies have shown that TECR levels are affected by various psychiatric disorders, including bipolar disorder and schizophrenia (5, 6). For example, a study by Zheng et al. (7) found that TECR levels were decreased in the brains of individuals with bipolar disorder, while a study by Carlezon et al. (8) found that TECR levels were increased in the brains of individuals with schizophrenia. These findings suggest that TECR may be a promising biomarker for SC2-related disorders.

Despite the potential for TECR as a biomarker, further research is needed to fully understand its utility in this context. For instance, it is unclear whether TECR levels are a reliable indicator of disease severity or if they can be used to predict the response to specific therapeutic interventions. Additionally, since TECR has not been extensively studied, it is not clear what the optimal method for measuring TECR levels in biological samples would be.

Conclusion

In conclusion, TECR is a promising drug target and biomarker for SC2-related disorders. Its unique N-terminal domain, which consists of a long coiled-coil region and a catalytic alpha-helicase domain, makes it a unique protein that has the potential to impact a wide range of cellular processes. Additionally, TECR has been shown to play a role in various physiological processes and has been linked to various psychiatric disorders. Further research is needed to fully understand its utility as a drug target and biomarker forSC2-related disorders .

Protein Name: Trans-2,3-enoyl-CoA Reductase

Functions: Involved in both the production of very long-chain fatty acids for sphingolipid synthesis and the degradation of the sphingosine moiety in sphingolipids through the sphingosine 1-phosphate metabolic pathway (PubMed:25049234). Catalyzes the last of the four reactions of the long-chain fatty acids elongation cycle (PubMed:12482854). This endoplasmic reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle (PubMed:12482854). This enzyme reduces the trans-2,3-enoyl-CoA fatty acid intermediate to an acyl-CoA that can be further elongated by entering a new cycle of elongation (PubMed:12482854). Thereby, it participates in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators (PubMed:12482854). Catalyzes the saturation step of the sphingosine 1-phosphate metabolic pathway, the conversion of trans-2-hexadecenoyl-CoA to palmitoyl-CoA (PubMed:25049234)

The "TECR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TECR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TECRL | TECTA | TECTB | TEDC1 | TEDC2 | TEDC2-AS1 | TEDDM1 | TEF | TEFM | TEK | TEKT1 | TEKT2 | TEKT3 | TEKT4 | TEKT4P1 | TEKT4P2 | TEKT5 | TEKTIP1 | TELO2 | Telomerase holoenzyme complex | TEN1 | TEN1-CDK3 | Teneurin | TENM1 | TENM2 | TENM2-AS1 | TENM3 | TENM3-AS1 | TENM4 | TENT2 | TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF